Open access
Sep 2026
Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn’s Disease
This internally validated ML framework showed improving discrimination over longer horizons, with maintenance-phase IFX trough concentration emerging as the dominant predictor, supporting proactive therapeutic drug monitoring pending external multicenter validation.
Yu-Qing Guo, Yi-Ting Wang, Min Gao et al.
· Drug Design, Development and... · 0 citations